Subtype
Retinal Cell Neoplasm
CI-CAN-00001460Explore in graph →
Non-malignant15 active trials1 approved drugs2 evidence items
- NCIt
- C7061
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001460Explore in graph →
Clinical trials
110 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06424301 | Targeting NUDT21 siRNA Drugs for Patients With Refractory Retinoblastoma | recruiting | Early Phase 1 | 2 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT06972602 | High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed | recruiting | Early Phase 1 | 10 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT01466855 | A Study of Intra-Ophthalmic Artery Topotecan Infusion for the Treatment of Retinoblastoma(IARB1) | terminated | Early Phase 1 | 36 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Sep 14, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Jun 26, 2025source: clinicaltrials